The technology, which is patent pending, can be used to help identify cancer patients who would respond to immune checkpoint inhibition treatment.
The update includes several key initiatives such as a liquid biopsy database, a DoD-led longitudinal study, and NCI cloud collaborations with Amazon and Microsoft.
The company has been working with NGS-based ctDNA testing for some time in research, but has now made its first move into the clinical sphere.
The Johns Hopkins University spinout has shifted from being research-oriented to focusing on bringing clinical tests through regulatory requirements.
The companies will work together to develop two next-generation sequencing-based in vitro cancer diagnostics.
In addition to its clinical trials matchmaking service, Cure Forward offers a platform for cancer patients to access and share their genomic test data.
The company said it anticipates rapid growth and intends to move to a new Baltimore facility in 2016.
The convertible note funding is part of a larger Series A round currently underway.
Despite the findings of the Hopkins study, for practical and economic reasons many diagnostic laboratories currently only sequence tumor samples or do not believe the tumor-normal approach is necessary.
N-of-One will provide clinical interpretation services for genomic tests conducted as part of the New England Veterans' Integrated Service Network oncology program
Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.
Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.
The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.
In Science this week: genetically modified flu virus could be key to new live vaccines, and more.